安罗替尼联合吉西他滨和多西他赛二线及以上治疗骨肉瘤肺转移的临床疗效

Clinical effects of anlotinib combined with gemcitabine and docetaxel as second-line or later therapy in patients with lung metastasis of osteosarcoma

目的评估安罗替尼联合吉西他滨+多西他赛二线及以上治疗骨肉瘤肺转移患者的疗效与安全性。方法回顾性分析2016年1月至2022年12月上海市第六人民医院肿瘤内科接受安罗替尼联合吉西他滨+多西他赛二线及以上治疗的23例骨肉瘤肺转移患者的病例资料。主要研究终点为无进展生存期(PFS),次要研究终点包括客观缓解率、疾病控制率(DCR)以及不良反应发生情况。结果23例骨肉瘤肺转移患者中疾病稳定17例(74%),疾病进展6例(26%),DCR为74%,中位PFS为10.8个月(95%CI:1.4~20.2个月)。23例患者均发生不良反应,3~4级不良反应包括血小板减少(17%)、甲状腺功能减退(9%)、高血压(4%)、手足综合征(4%)、乏力(4%)、腹泻(4%)、白细胞减少(4%)以及气胸(4%)。结论安罗替尼联合吉西他滨+多西他赛二线及以上治疗骨肉瘤肺转移具有一定的疗效,耐受性较好。

AIM To evaluate the efficacy and safety of anlotinib combined with gemcitabine+docetaxel as second-line or later therapy in patients with lung metastasis of osteosarcoma.METHODS Case data of 23 patients with lung metastasis of osteosarcoma received anlotinib combined with gemcitabine+docetaxel as second-line or later therapy in the department of oncology of Shanghai Sixth People's Hospital from January 2016 to December 2022 were analysed retrospectively.The primary endpoint was progression-free survival(PFS).Secondary endpoints included objective response rate,disease control rate(DCR)and safety.RESULTS In the 23 patients with lung metastasis of osteosarcoma,17 patients(74%)achieved stable disease and 6 patients(26%)achieved progress disease,with DCR 74%.Median PFS was 10.8months(95%CI:1.4 to 20.2 months).All 23 patients experienced adverse reactions.Grade 3 or 4 adverse reactions included thrombocytopenia(17%),hypothyroidism(9%),hypertension(4%),hand-foot reaction(4%),fatigue(4%),diarrhea(4%),leukopenia(4%),and pneumothorax(4%).CONCLUSION Anlotinib combined with gemcitabine+docetaxel as second-line or later therapy can be used as an effective treatment with manageable toxicities for patients with lung metastasis of osteosarcoma.